MET Exon 14 Mutation–Positive NSCLC: FAQ Part 2

Listen to international lung cancer experts Luis Paz-Ares, MD, PhD; D. Ross Camidge, MD, PhD; and Karen L. Reckamp, MD, MS, as they answer audience questions from a live CCO Webinar on METex14 mutation–positive NSCLC, from guidance on biomarker testing to sequencing of immunotherapy with MET inhibitors in these patients.